推荐产品
等级
pharmaceutical primary standard
API类
indapamide
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
CC1Cc2ccccc2N1NC(=O)c3ccc(Cl)c(c3)S(N)(=O)=O
InChI
1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
InChI key
NDDAHWYSQHTHNT-UHFFFAOYSA-N
基因信息
human ... SLC12A3(6559)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Indapamide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Indapamide Tablets
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Warning
危险声明
危险分类
Lact. - Repr. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
J Sassard et al.
Fundamental & clinical pharmacology, 19(6), 637-645 (2005-11-30)
The relationship between blood pressure (BP) and cardiovascular risk is clearly established; hypertension increases the rate of cardiovascular. High systolic blood pressure (SBP) may be the main parameter involved in cardiovascular morbidity and mortality. The benefit of lowering BP, particularly
Stéphane Laurent
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 21(3), S11-S18 (2003-08-22)
To review the safety and efficacy of the very-low-dose combination of perindopril 2 mg and indapamide 0.625 mg (Per2/Ind0.625) in essential hypertension, in relation to blood pressure control and target-organ damage. We included in this review several double-blind, randomized studies
John Chalmers et al.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 26(3), S21-S27 (2009-04-15)
The ADVANCE trial was designed to determine the effects of routine blood pressure lowering using a fixed combination of perindopril-indapamide on major vascular outcomes in patients with type 2 diabetes, regardless of initial blood pressure levels or the use of
A J Matheson et al.
Drugs, 61(8), 1211-1229 (2001-07-24)
The fixed low-dose combination of the ACE inhibitor perindopril and the non-thiazide diuretic indapamide has been evaluated in the management of patients with mild to moderate hypertension. Combination therapy aims to improve overall therapeutic efficacy while minimising adverse effects. In
J J Mourad et al.
Current medical research and opinion, 25(9), 2271-2280 (2009-07-25)
Despite the widespread notion that controlling hypertension is essential to improve cardiovascular outcome, uncontrolled hypertension rates remain high. Fixed-dose combinations are used routinely to reduce the impact of hypertension. Treatment with fixed-combination perindopril/indapamide, for example, at the currently approved doses
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门